Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9130109 | 0.95 | KEAP1 (0.58) | ALOX15KEAP1SMN1; SMN2SIGMAR1CYP2D6 | |
| SCHEMBL2025055 | 0.92 | — | — | |
| SCHEMBL4559690 | 0.92 | ALOX15 (0.77) | ALOX15KEAP1SMN1; SMN2SIGMAR1CYP2D6 | |
| SCHEMBL7643516 | 0.92 | ALOX15 (0.77) | ALOX15KEAP1SMN1; SMN2SIGMAR1CYP2D6 | |
| SCHEMBL22691893 | 0.89 | ALOX15 (0.81) | ALOX15KEAP1SMN1; SMN2SIGMAR1HRH3 | |
| SCHEMBL17493165 | 0.87 | ALOX15 (0.68) | ALOX15KEAP1SMN1; SMN2SIGMAR1CYP2D6 | |
| SCHEMBL6276732 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL3671864 | 0.87 | ALOX15 (0.77) | ALOX15KEAP1SMN1; SMN2SIGMAR1HRH3 | |
| SCHEMBL13876470 | 0.87 | SMN1; SMN2 (0.61) | ALOX15KEAP1SMN1; SMN2SIGMAR1CYP2D6 | |
| SCHEMBL291327 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820749-B2 | Centrally active and orally bioavailable uncharged bisoxime antidotes for organophosphate poisoning and methods for making and using them | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-21 | — | — | US | disclosed |
| US-20220227724-A1 | CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE UNCHARGED BISOXIME ANTIDOTES FOR ORGANOPHOSPHATE POISONING AND METHODS FOR MAKING AND USING THEM | OAK RIDGE NATIONAL LABORATORY | 2022-07-21 | — | — | US | disclosed |
| WO-2020237079-A1 | CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE UNCHARGED BISOXIME ANTIDOTES FOR ORGANOPHOSPHATE POISONING AND METHODS FOR MAKING AND USING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-26 | — | — | WO | disclosed |
| EP-2638020-B1 | TRANSAMINATION OF NITROGEN-CONTAINING COMPOUNDS TO MAKE CYCLIC AND CYCLIC/ACYCLIC POLYAMINE MIXTURES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-8993759-B2 | Transamination of nitrogen-containing compounds to make cyclic and cyclic/acyclic polyamine mixtures | DOW GLOBAL TECHNOLOGIES LLC (US) | 2015-03-31 | — | — | US | disclosed |
| EP-2638020-A1 | TRANSAMINATION OF NITROGEN-CONTAINING COMPOUNDS TO MAKE CYCLIC AND CYCLIC/ACYCLIC POLYAMINE MIXTURES | Dow Global Technologies LLC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-20130231476-A1 | TRANSAMINATION OF NITROGEN-CONTAINING COMPOUNDS TO MAKE CYCLIC AND CYCLIC/ACYCLIC POLYAMINE MIXTURES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-09-05 | — | — | US | disclosed |
| WO-2012064483-A1 | TRANSAMINATION OF NITROGEN-CONTAINING COMPOUNDS TO MAKE CYCLIC AND CYCLIC/ACYCLIC POLYAMINE MIXTURES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227724-A1 | CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE UNCHARGED BISOXIME ANTIDOTES FOR ORGANOPHOSPHATE POISONING AND METHODS FOR MAKING AND USING THEM | BCHE, ACHE, FHIT | ALOX15 908/4885KEAP1 271/4885SMN1; SMN2 1520/4885 |
| US-11820749-B2 | Centrally active and orally bioavailable uncharged bisoxime antidotes for organophosphate poisoning and methods for making and using them | BCHE, ACHE, FHIT | ALOX15 908/4885KEAP1 271/4885SMN1; SMN2 1520/4885 |
| US-20130231476-A1 | TRANSAMINATION OF NITROGEN-CONTAINING COMPOUNDS TO MAKE CYCLIC AND CYCLIC/ACYCLIC POLYAMINE MIXTURES | SRM, NNMT, GNMT | ALOX15 4190/4885KEAP1 2181/4885SMN1; SMN2 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.